Also found in: Medical.
GLP-1Glucagon-Like Peptide 1(hormone)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Besides Asp122, the other common-key residues (Phe80, Asn82, Gln97, His99, and Tyr101) of GLP-1 receptor 3D structure for the 2 candidates and the control did not locate at the disordered region, so we could say that there was no significant influence on the shape of the main binding sites (Figure 4).
Drucker, University of Toronto, ON, Canada) secrete GLP-1 in response to a number of neurotransmitters and nutrients [26].
Exendin-4 is a naturally occurring peptide of 39-amino acids obtained from the venom of "Heloderma lizard venom," bearing a 53% homology to human GLP-1. The second amino acid residue in N-terminal region, (alanine for human GLP-1), is replaced by glycine in exenatide and exenatide LAR (long acting release).
GLP-1 (glucagon-like peptide 1) and GIP (gastric inhibitory peptide) are hormones that are formed by the digestive tract and that control food intake and numerous metabolic processes.
Reviewing medical literature, they analyzed the results of 25 clinical trials involving over 6,000 patients who had been given GLP-1.
"The effects of Fibersol-2 to increase hormones PYY and GLP-1 are particularly important, as these two hormones released from the intestine help tell your brain that you are full," said Dr.
Victoza is the second product of the GLP-1 class in the USA, challenging pioneer Byetta, launched by US-based Eli Lilly & Co (NYSE: LLY) in 2005.
The drug is similar to the human hormone GLP-1, which plays a key role in blood glucose modulation while slowing down food absorption and suppressing appetite, resulting in glycemic control, weight loss and no incremental risk of hypoglycemia.
Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Society's Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)
Given the medical community's long-term experience with treating patients with metformin, and metformin's lower cost, most of the physicians interviewed for this article advise using SGLT2 inhibitors and GLP-1 receptor agonists as second-line treatments.